Interestingly, considering that most PROTACs have been developed as potential anticancer agents, including degraders directed to PTPs mentioned above, different strategies were proposed to achieve selective release of active PROTACs into tumor cells, thus reducing toxic effects for normal tissues [115]. This evidence concerns the gene PTS and neoplasm.